These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34707081)

  • 1. Adverse Side Effects Associated with Corticosteroid Therapy: A Study in 39 Patients with Generalized Myasthenia Gravis.
    Johnson S; Katyal N; Narula N; Govindarajan R
    Med Sci Monit; 2021 Oct; 27():e933296. PubMed ID: 34707081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up.
    Kupersmith MJ
    J Neurol; 2009 Aug; 256(8):1314-20. PubMed ID: 19377863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management.
    Brunner NG; Berger CL; Namba T; Grob D
    Ann N Y Acad Sci; 1976; 274():577-95. PubMed ID: 183590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is enough attention being given to the adverse effects of corticosteroid therapy?
    Hougardy DM; Peterson GM; Bleasel MD; Randall CT
    J Clin Pharm Ther; 2000 Jun; 25(3):227-34. PubMed ID: 10886467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of prednisone on the progression from ocular to generalized myasthenia gravis.
    Monsul NT; Patwa HS; Knorr AM; Lesser RL; Goldstein JM
    J Neurol Sci; 2004 Feb; 217(2):131-3. PubMed ID: 14706214
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beneficial effects of corticosteroids on ocular myasthenia gravis.
    Kupersmith MJ; Moster M; Bhuiyan S; Warren F; Weinberg H
    Arch Neurol; 1996 Aug; 53(8):802-4. PubMed ID: 8759987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to treatment in pediatric ocular myasthenia gravis.
    Xu L; Castro D; Reisch JS; Iannaccone ST
    Muscle Nerve; 2020 Feb; 61(2):226-230. PubMed ID: 31650555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenia gravis, corticosteroids and osteoporosis prophylaxis.
    Smith GD; Stevens DL; Fuller GN
    J Neurol; 2001 Feb; 248(2):151. PubMed ID: 11284137
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of Corticosteroid Tapering Regimens in Myasthenia Gravis: A Randomized Clinical Trial.
    Sharshar T; Porcher R; Demeret S; Tranchant C; Gueguen A; Eymard B; Nadaj-Pakleza A; Spinazzi M; Grimaldi L; Birnbaum S; Friedman D; Clair B;
    JAMA Neurol; 2021 Apr; 78(4):426-433. PubMed ID: 33555314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular myasthenia gravis - How effective is low dose prednisone long term?
    Verma R; Wolfe GI; Kupersmith MJ
    J Neurol Sci; 2021 Jan; 420():117274. PubMed ID: 33360170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety of prednisone for ocular myasthenia gravis.
    Bruce BB; Kupersmith MJ
    J Neuroophthalmol; 2012 Sep; 32(3):212-5. PubMed ID: 22549563
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids for myasthenia gravis.
    Schneider-Gold C; Gajdos P; Toyka KV; Hohlfeld RR
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD002828. PubMed ID: 15846640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term prednisone followed by thymectomy in myasthenia gravis.
    Mann JD; Johns TR; Campa JF; Muller WH
    Ann N Y Acad Sci; 1976; 274():608-22. PubMed ID: 1066998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Childhood myasthenia gravis: clinical features and outcomes.
    Sri-udomkajorn S; Panichai P; Liumsuwan S
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S152-7. PubMed ID: 22043769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab alone is as effective as associated with steroids on naive patients with generalized myasthenia gravis.
    Héraud C; Bresch S; Landes-Château C; Bourg V; Lebrun-Frenay C
    J Neurol; 2024 Aug; 271(8):5197-5202. PubMed ID: 38836907
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical characteristics and prognosis of myasthenia gravis in older people.
    Evoli A; Batocchi AP; Minisci C; Di Schino C; Tonali P
    J Am Geriatr Soc; 2000 Nov; 48(11):1442-8. PubMed ID: 11083321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Different characteristics of nonthymomatous generalized myasthenia gravis with and without oropharyngeal involvement.
    Yu L; Li J; Ma S; Jiang J; Wang T; Gamliel Z; Jing Y; Zhang X; Krasna MJ
    Ann Thorac Surg; 2007 Nov; 84(5):1694-8. PubMed ID: 17954087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.